Jubilant Generics Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Jubilant Generics Limited Pharmaceutical Export Portfolio Dataset — 6 Products, $23.9M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Jubilant Generics Limited — Pharmaceutical Exporter Profile (2026) | 6 Products, $23.9M Trade | TransData Nexus

Jubilant Generics Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $23.9M Total Trade · DGFT Verified

Jubilant Generics Limited is an Indian pharmaceutical exporter with a total trade value of $23.9M across 6 products in 4 therapeutic categories. Based on 638 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Azithromycin ($6.9M), Atorvastatin ($5.8M), Esomeprazole ($5.2M).

Jubilant Generics Limited — Export Portfolio & Destination Treemap

Jubilant Generics Limited pharmaceutical export portfolio — 6 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is Jubilant Generics Limited? — Company Overview & Market Position

Jubilant Generics Limited, established on November 25, 2013, is a global pharmaceutical company headquartered in Noida, Uttar Pradesh, India. The company operates under the Corporate Identification Number (CIN) U24100UP2013FLC060821 and is registered as a public limited company. As of the latest available data, Jubilant Generics Limited has an authorized share capital of ₹20,000,000 and a paid-up capital of ₹13,084,990. The company employs between 1,001 and 5,000 individuals, reflecting its substantial operational scale. Jubilant Generics Limited specializes in the research, development, manufacturing, and distribution of generic pharmaceutical products, including tablets, capsules, syrups, and injections. Its product portfolio spans various therapeutic categories, such as cardiovascular, antibiotics, and gastrointestinal treatments. The company's official website is www.jubilantgenerics.com.

What Does Jubilant Generics Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Azithromycin$6.9M 2Atorvastatin

Product Portfolio — Top 6 by Export Value

Jubilant Generics Limited exports 6 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Azithromycin	Antibiotics	$6.9M	164	3.8%	6
2	Atorvastatin	Cardiovascular	$5.8M	115	0.5%	13
3	Esomeprazole	Gastrointestinal	$5.2M	179	1.1%	10
4	Valsartan	Cardiovascular	$4.2M	85	2.1%	9
5	Irbesartan	Cardiovascular	$1.3M	84	1.2%	11
6	Valacyclovir	Antivirals	$537.8K	11	0.3%	7

Jubilant Generics Limited exports 6 pharmaceutical products across 4 therapeutic categories with a total export value of $23.9M. The top category is Cardiovascular (47.0% of portfolio), followed by Antibiotics (29.0%), indicating a concentrated portfolio with the top 5 products accounting for 97.7% of total export value.

Jubilant Generics Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Jubilant Generics Limited operates multiple manufacturing facilities across India, each designed to meet stringent international regulatory standards. These facilities are routinely inspected and accredited by agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Japan Pharmaceuticals and Medical Devices Agency (PMDA), the Therapeutic Goods Administration (TGA) of Australia, and the World Health Organization (WHO). The company's manufacturing capabilities include the production of immediate-release and modified-release oral solids, oral powders for solution or suspension, and other dosage forms. This diverse manufacturing expertise enables Jubilant Generics Limited to cater to a wide range of therapeutic segments, including cardiovascular, central nervous system, and gastrointestinal treatments.

3Key Leadership

As of the latest available information, the key leadership at Jubilant Generics Limited includes:

Dr. Jaidev Sanjeev Rajpal: Managing Director & CEO

Mr. Pramod Yadav: Director

Ms. Sudha Pillai: Director

These leaders are responsible for steering the company's strategic direction and ensuring compliance with global pharmaceutical standards.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Jubilant Generics Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Jubilant Generics Limited has established a significant presence in several regulated markets, including the United States, Europe, Canada, Japan, and Australia. In the United States, the company has made 98 Abbreviated New Drug Application (ANDA) filings for solid dosage formulations, with 56 products commercialized as of December 2019. In Europe, the company has obtained Certificates of Suitability (CEP) for 49 active pharmaceutical ingredients (APIs) and has 65 APIs registered with the European Directorate for the Quality of Medicines & HealthCare (EDQM). In Japan, Jubilant Generics Limited has filed 15 Japanese Drug Master Files (J-DMFs), indicating a strong foothold in the Japanese market. The company's manufacturing facilities are inspected and accredited by regulatory agencies such as the U.S. FDA, EMA, Japan PMDA, TGA Australia, and WHO, ensuring compliance with international standards.

2Emerging Markets

Jubilant Generics Limited is actively expanding its presence in emerging markets, including Africa, Latin America, and Southeast Asia. The company's commitment to quality is demonstrated by its manufacturing facilities being routinely inspected and accredited by international regulatory agencies such as the WHO. This adherence to global standards facilitates access to these emerging markets, enabling the company to meet the growing demand for affordable and high-quality generic pharmaceuticals in these regions.

Jubilant Generics Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Jubilant Generics Limited's manufacturing facilities have been subject to inspections by the U.S. Food and Drug Administration (FDA). In August 2018, the FDA conducted an inspection of the company's facility in Uttar Pradesh, India, identifying violations related to current good manufacturing practice (CGMP) regulations. The FDA issued a warning letter on March 6, 2019, citing these violations. The company responded to the warning letter, and the FDA evaluated the corrective actions taken. On April 23, 2024, the FDA issued a closeout letter, indicating that the company had addressed the violations. This sequence of events underscores the company's commitment to compliance with FDA regulations and its proactive approach to rectifying identified issues.

2WHO & EU GMP

Jubilant Generics Limited's manufacturing facilities are routinely inspected and accredited by international regulatory agencies, including the World Health Organization (WHO) and the European Medicines Agency (EMA). These accreditations demonstrate the company's adherence to global standards for good manufacturing practices (GMP), ensuring the production of high-quality pharmaceutical products. The company's commitment to maintaining these certifications reflects its dedication to meeting the stringent requirements of international markets.

Jubilant Generics Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Jubilant Generics Limited operates in a competitive landscape alongside other major pharmaceutical companies such as Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Ltd., Cipla Ltd., Zydus Lifesciences Ltd., and Lupin Ltd. These competitors have established significant market shares in various therapeutic segments. Jubilant Generics Limited's focus on high-quality generic formulations, including complex dosage forms like MUPS-based products, orodissolving tablets, and chewable tablets, differentiates it in the market. The company's strategic emphasis on therapeutic areas such as cardiovascular, central nervous system, and gastrointestinal treatments positions it to address specific market needs and compete effectively.

2Key Differentiators

Jubilant Generics Limited's key differentiators include its vertically integrated operations, which encompass research and development, manufacturing, and distribution of generic pharmaceutical products. The company's in-house active pharmaceutical ingredient (API) capabilities provide a stable source of supply, ensuring product availability at competitive prices. Additionally, Jubilant Generics Limited's focus on complex dosage forms, such as MUPS-based products, orodissolving tablets, and chewable tablets, demonstrates its commitment to innovation and meeting diverse patient needs. The company's global presence in over 50 countries, including the United States, Europe, Canada, Japan, and Australia, reflects its extensive market reach and operational scale.

Frequently Asked Questions — Jubilant Generics Limited

How many pharmaceutical products does Jubilant Generics Limited export from India?

Jubilant Generics Limited exports 6 pharmaceutical products across 4 therapeutic categories. The top exports are Azithromycin ($6.9M), Atorvastatin ($5.8M), Esomeprazole ($5.2M), Valsartan ($4.2M), Irbesartan ($1.3M). Total export value is $23.9M.

What is Jubilant Generics Limited's total pharmaceutical export value?

Jubilant Generics Limited's total pharmaceutical export value is $23.9M, based on 638 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Jubilant Generics Limited cover?

Jubilant Generics Limited exports across 4 therapeutic categories. The largest are Cardiovascular (47.0%, 3 products), Antibiotics (29.0%, 1 products), Gastrointestinal (21.7%, 1 products).

Get Full Jubilant Generics Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.